Cyberonics to Host Investor and Analyst Meeting in Boston

• Press Release
• Source: Cyberonics, Inc.
• On 9:00 am EST, Tuesday November 10, 2009

HOUSTON, Nov. 10 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX - News) today announced it will host an investor and analyst meeting on Friday, December 4, 2009 at the Westin Copley Place in Boston, Massachusetts. The meeting, which also will be webcast live, will begin at 9:00 a.m. eastern time and end at approximately 12:30 p.m. eastern time.

Presentations on current epilepsy treatments, VNS Therapy(TM) and the future role that medical devices will play in addressing the needs of patients with epilepsy will be made by:

• Angus Wilfong, M.D., Associate Professor, Pediatrics and Neurology, Baylor College of Medicine; Medical Director, Comprehensive Epilepsy Program, Texas Children's Hospital; and
• Steven Karceski, M.D., Associate Clinical Professor of Neurology, College of Physicians and Surgeons, Columbia University.

In addition, presentations on Cyberonics' development priorities and timelines, U.S. and International market potential and replacement trends will be made by:

• Dan Moore, Cyberonics' President & Chief Executive Officer;
• Milton Morris, Ph.D., Vice President, Research & Development; and
• James Reinstein, Vice President, Sales & Marketing and General Manager, International.

Institutional investors and analysts interested in attending the investor and analyst meeting should contact Jackie Baumgartner at 1-281-228-7229 or Jackie.Baumgartner@cyberonics.com.

This meeting will be webcast live and by replay and will include the slides from the meeting. To access the webcast, please enter the Company's website at http://www.cyberonics.com, then follow the webcast link listed under Recent Presentations.

About Cyberonics, Inc. and VNS Therapy(TM)

Cyberonics, Inc. (Nasdaq: CYBX - News) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at www.cyberonics.com and www.vnstherapy.com.

    CONTACT INFORMATION:
    Greg Browne, CFO
    Cyberonics, Inc.
    100 Cyberonics Blvd.
    Houston, TX 77058
    Main:  (281) 228-7262
    Fax:  (281) 218-9332
    ir@cyberonics.com

Buzz up!